INS and gastric cancer: Last year, similarly to our study, Baglia et al. showed significantly worse survival results in diabetic patients with gastric cancer using sulfonylurea (HR 2.05 [95% CI 1.09–3.84]) or insulin (HR 1.45 [95% CI, 0.99–2.10]) and no effect with metformin use (HR 1.01 [95% CI 0.48–2.12]) [34].